Apologies if this was previously posted here:
We found that COVID-19 patients exhibit dramatic increases in autoantibody reactivities compared to uninfected controls, with a high prevalence of autoantibodies against immunomodulatory proteins including cytokines, chemokines, complement components, and cell surface proteins. We established that these autoantibodies perturb immune function and impair virological control by inhibiting immunoreceptor signaling and by altering peripheral immune cell composition, and found that murine surrogates of these autoantibodies exacerbate disease severity in a mouse model of SARS-CoV-2 infection.
Ooof on the bolded part.Of 30 557 persons tested in Geneva during the study period, 18.1% tested positive (n = 5534); 22.2% of these were hospitalized (n = 1229), and 703 enrolled in COVICARE follow-up. Out of the initial cohort, 669 persons were ultimately included (Figure 1). The mean age was 42.8 years (SD, 13.7); 60% of included patients were women, 24.6% were health care workers, and 68.8% had no underlying risk factors.
At 30 to 45 days (mean, 43 days) from diagnosis, at least 32% of the 669 originally included patients reported 1 or more symptoms. Fatigue, dyspnea, and loss of taste or smell were the main persistent symptoms. Participants not reached between days 30 and 45 (n = 159) had similar characteristics to those reached in that period
Coronavirus disease 2019 can persist and result in prolonged illness. Our study shows persistence of symptoms in a third of ambulatory patients 30 to 45 days after diagnosis even if we assume that those lost to follow-up were all asymptomatic. Fatigue, dyspnea, and loss of taste or smell were the main persistent symptoms. These results are in line with a recent study of 274 participants that reported the persistence of symptoms 14 to 21 days after diagnosis (2).
Maybe there's a better thread for this but it suggests a possible mechanism for long-term symptoms that seems to reflect prior ME research. Obligatory: in mice.
Diverse Functional Autoantibodies in Patients with COVID-19
https://www.medrxiv.org/content/10.1101/2020.12.10.20247205v2
Dramatic levels of “friendly fire” from the immune system may drive severe Covid-19 disease and leave patients with “long Covid” – when medical problems persist for a significant time after the virus has been beaten – scientists have said.
Researchers at Yale University found that Covid-19 patients had large numbers of misguided antibodies in their blood that targeted the organs, tissues and the immune system itself, rather than fighting off the invading virus.
The scientists compared immune responses in patients and uninfected people and discovered scores of aberrant antibodies in the former.These blocked antiviral defences, wiped out helpful immune cells, and attacked the body on multiple fronts, from the brain, blood vessels and liver to connective tissue and the gastrointestinal tract.
https://www.rcot.co.uk/node/3540Post-viral fatigue is when you have an extended period of feeling unwell and fatigued after a viral infection.
Fatigue is a normal part of the body’s response to fighting a viral infection such as COVID-19. Fatigue is likely to continue for some time after the infection has cleared. It can make you sleep more, feel unsteady on your feet, make standing for long periods difficult, as well as affecting your ability to concentrate and your memory.
This webinar is a patient-led discussion on how Long Covid is depicted in the media and in research, and how health services should respond to meet people’s needs. The panel of experts by experience address some of the myths that currently surround the experience of Covid infection before answering questions on the variation of service provision, education for healthcare professionals and outstanding research questions.
https://youtu.be/wZ_ipmf0s-Q
I think a large proportion of people with long covid will recover within a year as I think a large number of people with PVF do. That's why I would prefer that ME/CFS was diagnosed after a year and it remained PVF to that point.